

Novel Immunogenic Antigens of *Shigella*

- It relates to the product novel immunogenic protein antigens that are common to *Shigella* spp.
- The vaccine confers broad protection against three epidemiologically most relevant serotypes of *Shigella* across the globe.
- **Milestones achieved:**
 - **IP Status:** US patent has been granted with patent no. 9,636,390
 - **Validation:** Animal study of a mixture of these peptides using TH1 adjuvants has been cleared for human use.
- **USP of technology:**
 - a. These novel immunogenic protein antigens help in development of an effective *Shigella* vaccine which gives broad spectrum protection against different serotypes of *Shigella*
 - b. It could also be used in immuno-diagnosis of *Shigella* spp.
- Technology was developed at Department of Medical Microbiology, Post graduate Institute of Medical Education and Research, Chandigarh and supported by ICMR.
- ICMR is seeking potential collaborators for the validation of technology.